These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 17278264)

  • 21. Monoclonal antibody anti-MPO is useful in recognizing minimally differentiated acute myeloid leukaemia.
    Praxedes MK; De Oliveira LZ; Pereira Wda V; Quintana IZ; Tabak DG; De Oliveira MS
    Leuk Lymphoma; 1994 Jan; 12(3-4):233-9. PubMed ID: 8167554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia.
    Vollmer M; Li L; Schmitt A; Greiner J; Reinhardt P; Ringhoffer M; Wiesneth M; Döhner H; Schmitt M
    Br J Haematol; 2003 Mar; 120(6):1000-8. PubMed ID: 12648070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonlinearity of measurements of a tumor marker for breast cancer.
    Cooper EH; Forbes MA; Laurence V; Beya MF; de Chastonay J
    Clin Chem; 1990 Feb; 36(2):408-9. PubMed ID: 2406045
    [No Abstract]   [Full Text] [Related]  

  • 24. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Carcinoembryonic antigen level in peritoneal washing is a prognostic factor in patients with gastric cancer.
    Irinoda T; Terashima M; Takagane A; Sasaki N; Abe K; Araya M; Nishizuka S; Yonezawa H; Nakaya T; Shimooki O; Oyama K; Ikeda K; Saito K
    Oncol Rep; 1998; 5(3):661-6. PubMed ID: 9538172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour marker immunoreactivity in adenocarcinoma.
    Ellis IO; Hitchcock A
    J Clin Pathol; 1988 Oct; 41(10):1064-7. PubMed ID: 3192728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sweet beginning for cancer stem cells.
    Baum LG
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):815-6. PubMed ID: 26772316
    [No Abstract]   [Full Text] [Related]  

  • 28. Limitations of tumour markers in screening.
    Roulston JE
    Br J Surg; 1990 Sep; 77(9):961-2. PubMed ID: 2095760
    [No Abstract]   [Full Text] [Related]  

  • 29. [Fundamental and clinical evaluation of ELSA CA 72-4 kit for serum CA 72-4 antigen].
    Omori S; Murakami M; Fukuchi M
    Kaku Igaku; 1990 Jun; 27(6):667-75. PubMed ID: 2214330
    [No Abstract]   [Full Text] [Related]  

  • 30. Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer.
    Terashima S; Takano Y; Ohori T; Kanno T; Kimura T; Motoki R; Kawaguchi T
    Surg Today; 1998; 28(7):682-6. PubMed ID: 9697259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia.
    Guinn BA; Gilkes AF; Mufti GJ; Burnett AK; Mills KI
    Br J Haematol; 2006 Jul; 134(2):238-9. PubMed ID: 16846483
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic value of CA 19.9 levels in colorectal cancer.
    Filella X; Molina R; Grau JJ; Piqué JM; Garcia-Valdecasas JC; Astudillo E; Biete A; Bordas JM; Novell A; Campo E
    Ann Surg; 1992 Jul; 216(1):55-9. PubMed ID: 1632702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis.
    Brouwer RE; Hoefnagel J; Borger van Der Burg B; Jedema I; Zwinderman KH; Starrenburg IC; Kluin-Nelemans HC; Barge RM; Willemze R; Falkenburg JH
    Br J Haematol; 2001 Nov; 115(2):298-308. PubMed ID: 11703324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy.
    Campos L; Guyotat D; Archimbaud E; Devaux Y; Treille D; Larese A; Maupas J; Gentilhomme O; Ehrsam A; Fiere D
    Br J Haematol; 1989 Jun; 72(2):161-6. PubMed ID: 2757962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival.
    Nakamaki T; Hamano Y; Hisatake J; Yokoyama A; Kawakami K; Tomoyasu S; Honma Y; Koeffler P
    Br J Haematol; 2003 Oct; 123(1):72-80. PubMed ID: 14510945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Difference in tissue expression of tumour markers CA 19-9 and CA 50 in hepatocellular carcinoma and cholangiocarcinoma.
    Haglund C; Lindgren J; Roberts PJ; Nordling S
    Br J Cancer; 1991 Mar; 63(3):386-9. PubMed ID: 1848439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor markers for early diagnosis of cholangiocarcinoma.
    Sirisinha S
    Asian Pac J Allergy Immunol; 1989 Jun; 7(1):1-3. PubMed ID: 2546569
    [No Abstract]   [Full Text] [Related]  

  • 38. Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer.
    Louhimo J; Kokkola A; Alfthan H; Stenman UH; Haglund C
    Int J Cancer; 2004 Oct; 111(6):929-33. PubMed ID: 15300805
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunodiagnosis of ovarian tumors.
    Jacobs I; Bast RC
    Immunol Ser; 1990; 53():323-38. PubMed ID: 2100566
    [No Abstract]   [Full Text] [Related]  

  • 40. Competing causes of death in young cases of myeloid leukaemia.
    Stewart A
    Paediatr Perinat Epidemiol; 1987 Sep; 1(2):197-8. PubMed ID: 3506200
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.